Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmad Kadhim

Gastroenterology Williamsville, NY Medical Doctor

NPI 1386892479 CMS profile 1199923

5225 Sheridan Dr, Williamsville, NY 14221

Open in the dashboard

General payments

$155,324

629 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmad Kadhim of Williamsville, NY is reported in the CMS Open Payments database as having received $155,324 across 629 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,582 168
2024 General $69,244 154
2023 General $1,997 61
2022 General $1,019 26
2021 General $13,600 126
2020 General $526 30
2019 General $8,358 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmad Kadhim
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ahmad Kadhim were reported at $60,582. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ahmad Kadhim Gastroenterology median Middle half National median
2019 $8,358 $417 $126–$1,100 $163
2020 $526 $224 $74–$624 $114
2021 $13,600 $352 $106–$1,054 $132
2022 $1,019 $448 $129–$1,270 $149
2023 $1,997 $533 $150–$1,390 $160
2024 $69,244 $605 $160–$1,606 $164
2025 $60,582 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $75,891 180 payments
  2. Phathom Pharmaceuticals, Inc. $27,454 40 payments
  3. Pfizer Inc. $24,288 63 payments
  4. AbbVie, Inc. $14,933 150 payments
  5. Allergan Inc. $7,705 24 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $921 49 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $565 28 payments
  8. Lilly USA, LLC $326 9 payments
  9. Ferring Pharmaceuticals Inc. $290 13 payments
  10. Gilead Sciences, Inc. $266 5 payments
  11. Other $2,685 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $124,377 51 payments
  2. Food and Beverage $15,710 552 payments
  3. Travel and Lodging $15,174 21 payments
  4. Gift $36 1 payment
  5. Education $27 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $74,979 112 payments
  2. STELARA $33,086 93 payments
  3. VOQUEZNA $27,425 38 payments
  4. VELSIPITY $24,006 40 payments
  5. LINZESS $16,172 42 payments
  6. VIBERZI $2,656 8 payments
  7. RINVOQ $1,283 34 payments
  8. HUMIRA $773 36 payments
  9. SKYRIZI $740 18 payments
  10. MAVYRET $540 34 payments
  11. Other $6,579 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

377

Median for Gastroenterology: 569

Drug cost

$38,651

Median for Gastroenterology: $104,976

Branded share of claims

10.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 28 $32,784
Pantoprazole Sodium Generic 160 $2,660
Dicyclomine Hcl Generic 60 $1,160
Omeprazole Generic 72 $907
Famotidine Generic 31 $592
Ondansetron Odt Ondansetron Brand 13 $491
Metoclopramide Hcl Generic 13 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$30,161

Medicare's payments for the services billed

Medicare patients

186

Average age 68

Services billed

293

100 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 35%
Ischemic heart disease 34%
Chronic kidney disease 32%
Heart failure 27%
Depression 27%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VELSIPITY
  • PFIZER INC. $18,688
$18,688 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $17,579
$17,579 — —
STELARA
  • Janssen Biotech, Inc. $15,974
$15,974 — —
TREMFYA
  • Janssen Biotech, Inc. $15,711
$15,711 — —
RINVOQ
  • AbbVie, Inc. $276
$276 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

629 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record